News

This September our global community has come together once again to partake in worldwide awareness-raising campaigns around dementia and Alzheimer’s. From Bermuda to Zimbabwe to Scotland and Sri Lanka, ADI’s member organisations have hosted powerful community events and have encouraged people all over the world to ask about dementia, and ask about Alzheimer’s. Some of ADI’s World Alzheimer's Month activities included the launch of the 2025 World Alzheimer Report and a side event co-hosted with the WHO at the United Nations General Assembly ahead of the 4th High-Level Meeting on Non-Communicable Diseases.

After two years of dedicated and persistent advocacy by ADI, dementia will, for the first time, be formally recognised within the new UN Political Declaration on noncommunicable diseases (NCDs) and mental health, as a leading NCD.

DY Suharya, ADI’s Asia Pacific Regional Director participated in the Walk the Talk for Dementia from Sarria to Santiago de Compostela in Spain.

On 13 August, Argentina’s Health and Budget Committees approved the Dementia Bill, marking a major step towards the country’s first National Dementia Plan. Congressman and neuroscientist Facundo Manes urged the government to allocate funding for the law, which now moves to the full Chamber of Deputies before reaching the Senate. ADI welcomes this development as Argentina advances towards making dementia a national health priority.

1 September marks the beginning of World Alzheimer’s Month. This year, we are raising awareness and encouraging our global network and beyond to ask more questions about dementia.

As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue. 

This month, ADI’s Regional Director for the Asia Pacific, DY Suharya, partook in a number of important meetings and events both in Lyon, France at the WHO Academy, and in Hanoi, Vietnam, alongside Vietnam International Organisation for Better Ageing (VIOBA), who are currently partaking in ADI’s Membership Development Programme.

This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.